ALP

2.10012.50%
RA

Robert A. Kramer

Chief Scientific Officer

Dr. Robert A. Kramer, also known as Rob, Ph.D., serves as the Chief Scientific Officer at Alpha Compute Corp (formerly known as AlphaTON Capital Corp.) (formerly known as Portage Biotech Inc.) since January 8, 2019. He is Scientific Advisor at Stimunity SAS. He served as a Scientific Advisor of Aro Biotherapeutics Company until May 2022. He serves as CSO of the SalvaRx Group and serves on several Boards for both the Pharmaceutical and Biotechnology Industry. He served as Member of Scientific Advisory Board at Compass Therapeutics, Inc since October 2019 until 2022. He was Global Head of Oncology Drug Discovery at Janssen (Johnson & Johnson company). Dr. Kramer has been a Member of Scientific Advisory Board at HBM Holdings Limited since December 2016. Dr. Kramer was Vice President of Oncology and Immunology Drug Discovery at Bristol-Myers Squibb from 1995 to 2010, where he oversaw the Princeton, New Jersey research site, including more than 250 scientists and 40 preclinical programs. He championed immunotheraphy at Bristol-Myers Squibb, resulting in the acquisition of Medarex, Inc. in 2009 and its portfolio of immune therapeutics that included Ipilimumab and Nivolumab. Dr. Kramer has been a Director of Meditope Biosciences, Inc since January 06, 2015. He also championed immune oncology programs such as PD-1, an immune checkpoint agent that is a target for several new oncology drugs in development. Dr. Kramer served for five years from 1986 to 1991 as Assistant Professor in the Department of Radiation Therapy at Harvard Medical School and he conducted his postdoctoral work at the National Institutes of Health. He is a grant reviewer for the Pharmaceutical Manufacturers Association and the State of Texas (CPRIT) and is also Vice President of the Cancer Molecular Therapeutics Research Association which organizes an annual conference on novel approaches to cancer therapy. Dr. Kramer is an accomplished scientist and researcher who has successfully secured National Institutes of Health (NIH) funding and has over 40 peer-reviewed publications. He serves as Member of Scientific Advisory Board at Tavotek Biotherapeutics Ltd. He earned his Ph.D. in pharmacology at the University of Vermont and holds a B.S. in biology from SUNY at Stonybrook. He undertook his post doctorate studies at the National Cancer Institute.

公司職務